What Is CagriSema? The Next-Generation Weight Loss Compound

TL;DR: CagriSema is Novo Nordisk’s investigational co-formulation combining cagrilintide (a long-acting amylin analog) with semaglutide (GLP-1 agonist). The dual mechanism targets two distinct metabolic pathways simultaneously — amylin signaling and GLP-1 signaling — producing additive or synergistic effects on weight reduction. REDEFINE phase 3 data showed ~22-25% weight loss, exceeding semaglutide alone. Both component peptides are available individually as research compounds.

Research Disclaimer: This article is for informational and research purposes only. NorthPeptide does not sell CagriSema or semaglutide. Cagrilintide is available as a research peptide for laboratory use only. This content does not constitute medical advice.

By NorthPeptide Research Team — April 19, 2026

Introduction

The GLP-1 receptor agonist class — exemplified by semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — has redefined pharmacological approaches to obesity and metabolic disease. The question driving the next wave of drug development is: how much further can weight loss be pushed? CagriSema is Novo Nordisk’s most advanced answer to that question.

By combining two mechanistically distinct weight-regulating compounds — cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) — into a single weekly injection, CagriSema targets the obesity phenotype from two separate biological axes. The clinical data emerging from the REDEFINE program is establishing CagriSema as a credible challenger to tirzepatide and a potential bridge to the kind of weight loss outcomes previously only achievable with bariatric surgery.

The Two Components: Cagrilintide and Semaglutide

Cagrilintide: The Amylin Analog

Amylin is a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells in response to meals. It complements insulin’s glucose-lowering action through several mechanisms:

• Satiety: Amylin acts on the area postrema and nucleus tractus solitarius in the brainstem to reduce meal size and increase satiety
• Gastric emptying: Slows postprandial gastric emptying, reducing the rate of nutrient absorption and blunting glucose excursions
• Glucagon suppression: Inhibits postprandial glucagon secretion from pancreatic alpha cells
• Body weight regulation: Chronic amylin receptor activation produces sustained reductions in body weight through hypothalamic and brainstem pathways

Native human amylin is pharmacologically impractical — it has a very short half-life and tends to aggregate (the same aggregation property underlies the islet amyloid deposits seen in type 2 diabetes). Pramlintide, an FDA-approved amylin analog, improved stability but still required twice or three times daily injection.

Cagrilintide is a long-acting amylin analog engineered by Novo Nordisk with a fatty acid modification that enables albumin binding and extends the half-life to approximately one week — matching semaglutide’s dosing interval and enabling the once-weekly co-formulation that is CagriSema.

Semaglutide: The GLP-1 Agonist

Semaglutide is Novo Nordisk’s GLP-1 receptor agonist with an ~7-day half-life. Its mechanisms are well established: glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite suppression through hypothalamic GLP-1R activation. The STEP program demonstrated 14.9–17% body weight reduction at 2.4 mg once weekly.

The Dual Mechanism: Why Combination Works

The rationale for combining amylin and GLP-1 signaling is mechanistic complementarity. The two pathways operate through different receptors, different neuroanatomical targets, and different aspects of energy homeostasis:

The non-overlapping receptor targets mean that combining these two peptides should produce additive, and potentially synergistic, effects on weight regulation. Preclinical studies in rodent models of obesity confirmed additive weight loss effects when amylin and GLP-1 agonism were combined — more than either alone. This preclinical hypothesis drove the clinical development program.

CagriSema: The Co-formulation

CagriSema is a fixed-ratio co-formulation of cagrilintide 2.4 mg and semaglutide 2.4 mg, administered as a single once-weekly subcutaneous injection. The co-formulation was a significant pharmaceutical engineering challenge: the two peptides needed to remain stable in the same vial and needle without interacting or degrading each other.

The final formulation uses a fixed ratio that allows dose escalation — patients start at lower doses and escalate over approximately 32 weeks to the target dose of 2.4 mg/2.4 mg, reducing gastrointestinal side effects during the escalation period.

REDEFINE Clinical Program: The Weight Loss Data

REDEFINE 1 (Phase 3)

REDEFINE 1 enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes. Key results at 68 weeks:

• Mean weight loss: 22.7% from baseline with CagriSema 2.4 mg/2.4 mg, versus 7.1% with placebo (p<0.0001)
• ≥20% weight loss: Achieved by approximately 51% of CagriSema participants, versus 7% with placebo
• ≥25% weight loss: Achieved by approximately 34% of CagriSema participants
• This compares to STEP 1 (semaglutide 2.4 mg alone): 14.9% mean weight loss, with ~33% achieving ≥20%

REDEFINE 2 (Phase 3, Type 2 Diabetes)

REDEFINE 2 enrolled adults with type 2 diabetes and obesity/overweight. Results at 68 weeks:

• Mean weight loss: 15.6% with CagriSema, versus 3.5% with placebo
• HbA1c reduction: -1.8% with CagriSema versus -0.3% with placebo
• Results in the T2D population are lower than in non-diabetic subjects — consistent with what has been observed across the GLP-1 class (diabetes attenuates weight loss response)

Comparison to Other Weight Loss Compounds

CagriSema’s 22.7% mean weight loss positions it between tirzepatide and retatrutide — exceeding semaglutide monotherapy by approximately 8 percentage points and demonstrating the additive value of the amylin component.

Side Effect Profile

The side effect profile of CagriSema reflects both its component compounds:

• Gastrointestinal effects: Nausea, vomiting, diarrhea, and constipation are the most common adverse events, consistent with GLP-1 agonist class effects. The incidence was similar to or slightly higher than semaglutide alone in early dose escalation.
• Injection site reactions: Slightly more common than with semaglutide alone, reflecting the higher total peptide concentration at the injection site.
• Cardiovascular effects: Small increases in heart rate (approximately 5-6 bpm) have been observed — this is a class effect of both amylin analogs and GLP-1 agonists.
• No new safety signals: Across the REDEFINE program, no safety signals emerged that were not already associated with the individual components in monotherapy trials.

Notably, the additive weight loss of CagriSema did not come with a proportionally additive increase in adverse events — suggesting that the two mechanisms may produce synergistic efficacy with roughly additive tolerability.

Development Timeline

• 2019–2021: Phase 1/2 dose-finding studies for cagrilintide monotherapy and CagriSema combination
• 2021: Phase 2 CagriSema study published — 8 mg/2.4 mg combination showed 15.6% weight loss at 20 weeks
• 2022–2024: REDEFINE Phase 3 program initiated (REDEFINE 1, 2, 3, 4, 5 across multiple indications)
• 2024: REDEFINE 1 and 2 results reported
• 2025–2026: Regulatory submission and review period (FDA NDA/BLA application anticipated)
• 2026+: Anticipated regulatory approval decision; commercial launch contingent on approval

Implications for Peptide Research

CagriSema’s development has several implications for researchers in the metabolic and weight management space:

• Amylin receptor as a target: CagriSema validates the amylin receptor as a meaningful secondary target for weight management beyond GLP-1. This opens research interest in other amylin analogs and receptor modulators.
• Multi-mechanism combination approaches: The success of combinations (tirzepatide: GLP-1+GIP; CagriSema: GLP-1+amylin; retatrutide: GLP-1+GIP+glucagon) demonstrates that multi-agonist and multi-mechanism approaches consistently outperform single-target agents. This principle is now driving pipeline design across the field.
• Ceiling effects: With weight losses now approaching 22-25%, researchers are beginning to ask whether pharmacological approaches can match surgical weight loss (typically 25-35% long-term), and whether lean mass preservation becomes the limiting factor rather than absolute weight reduction.
• Lean mass considerations: Significant weight loss from any pharmacological agent includes lean mass loss. Research into combination approaches with anabolic agents (resistance exercise, anabolic peptides) to preserve muscle mass during GLP-1/amylin-driven weight loss is an active area.

Cagrilintide as a Research Peptide

Cagrilintide, the amylin analog component of CagriSema, is available in the NorthPeptide research catalog for laboratory research use. Researchers studying amylin receptor signaling, metabolic regulation, or appetite-satiety mechanisms may find cagrilintide relevant for in vitro or in vivo model work.

Cagrilintide (Research)
Retatrutide (Research)

Citations

1. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management in adults with overweight or obesity: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. PMID: 33894838
2. Lau J, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370-7380. PMID: 26308095
3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
5. Novo Nordisk. REDEFINE 1 Phase 3 results — CagriSema in adults with obesity. Press release, 2024. novonordisk.com
6. Frias JP, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385275